Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 30, 1996

View Archived Issues

Lidocaine topical patch effective in treating post-herpetic neuralgia

Merck & Co. reports NK1 antagonists

Treatment for keratinization disorders described by Janssen

Sepracoat given European Approval of Conformity Certificate

ADCON-L and ADCON-T/N research demonstrates efficacy

Dura obtains marketing rights of Lilly's cephalosporin antibiotics

Tetromycin A: a novel antibacterial agent

Antifungal agents from Hokko Kagaku

Influenza A virus sialidase inhibitors from Glaxo Wellcome

Antiherpes compounds from Bio-Mega/Boehringer Ingelheim

Toyama reveals anti-HIV quinolones

Paracelsian improves HIV-1 system model

Cytel receives phase I SBIR grant for AIDS vaccine development

Gene mutancy linked to natural HIV-1 infection resistance

Genetic sequence of AIDS-related disease revealed

Protease inhibitors described by Shionogi

VLA-4 receptor-blocking drugs described by Zeneca

Superoxide ion production inhibitors from Sagami

Aviron's intranasal influenza vaccine begins phase III

FDA approval requested for thymoglobin manufacturing process, facility

New agents for use in transplantation

AG-2034 granted approval for U.S. phase I initiation

Phase III trial on Onconase combination initiated

AltaRex and Medac finalize Ovarex partnership

Conjugates for cancer/infectious disease treatment covered by U.S. patent

LGD-1069 to enter pivotal U.S. trials

Inflazyme/SuperGen future licensing agreement

DNA cleaving reagents from the University of Cincinnati

Cancer genetics joint venture

Gene involved in colon cancer development revealed

BRCA1 licensing agreement

Minoxidil effective and safe for chemotherapy-induced hair loss in women

Study finds latanoprost more effective than timolol

Potent antiinflammatory/antioxidant agents from Alcon

Prophylactic tibolone shown effective in 2 year study

Estrogenic compounds from Sankyo

SDZ-266806: A novel squalene synthase inhibitor

More squalene synthase inhibitors from Pfizer

Xenical to be marketed in 1997

NGD-95-1 demonstrates safety in phase I

CCK antagonists from Warner-Lambert

Beta3-adrenoceptor agonists described by Dainippon

Cangene and Cheil Jedang sign Leucotropin agreement

CollaGenex signs European marketing agreement for Periostat

Biomira licenses MAb-170 to Neoprobe

Sonus regains EchoGen European marketing rights

ImaRx issued U.S. patent for contrast agents

Theratech describes new rheumatiod arthritis diagnosis

Flunitrazepam may alter circadian sleep-wake rhythms

BMS, Sano to collaborate on transdermal BuSpar development

Russian investigators describe new tranquilizer

DuPont Merck reports on CRH antagonists for anxiety, depression

Famotidine tested in schizophrenic patients

Correlation established between serum PLA2 activity and schizophrenia symptoms

Potential antipsychotic described by Parke-Davis

CGP-25454 tested in healthy volunteers

Zyn-Linker shows promising results in preclinicals

Activated Cell Therapy's cell processing devices earn FDA approval

Medtronic acquires catheter product line

Celox Laboratories' ViaStem covered under patent

DNX Corporation and BioClin International to merge

Cypress Bioscience/PRP merger imminent

Tegretol-XR launched in U.S.

Roche files for approval of Tasmar

Botulinum toxin effective in reducing upper limb spasticity

Botulinum toxin effective in treating writer's cramp

Prednisone suppresses acute phase in AD patients

Synapton phase III trials concluded

Memantine enters phase I for AIDS-related dementia, painful peripheral neuropathies

Pfizer reports new class of muscarinic agonists

CRM-1.13.1: Nicotinic agonist based on lobeline

Basic AD research advances reported

PLA2 role in Alzheimer's disease suggested

AChE inhibitor isolated from Penicillium at Kitasato Institute

Lilly's new AMPA antagonist, LY-311446

Scirex to manage IND filing for Apanol

SKB reports on PDE IV inhibitor research

SKB claims NK3 antagonists for pulmonary disorders

Endothelin converting enzyme inhibitor revealed by Schering-Plough

Kirin Brewery synthesizes agents for arteriosclerosis

MHC-II and related molecules for treating septic shock

Fujisawa obtains marketing rights for ReoPro

Glaxo Wellcome claims fibrinogen antagonists

Fibrinogen antagonists from Nippon Steel

Fibrinogen antagonists claimed by Thomae

TxA2/PGH2 antagonists described by Terumo

Antiplatelet agents described by Kissei

Terazosin and finasteride go head-to-head in BPH patients

U.S. agreement announced for ProstaFlo

Potential BPH therapeutics from Poli Industria Chimica

Reliance approved for marketing in U.S.

Taisho discloses agents for urinary incontinence

OP-1 role in kidney formation investigated

FDA approves Helidac for marketing

Provir effective in patients with travelers' diarrhea

Yamanouchi reveals 5HT3 agonist

Expanded H-BIG clinical development program announced

Positive efficacy/safety profile for maximal-dose sulfonylurea therapy reported

Sankyo reports novel hypoglycemic agents

Aldose reductase inhibitors from Terumo

Aldose reductase/5-lipoxygenase inhibitors reported by Tsumura

Merck & Co. reports on L-163689

CPC-111 clinical trial results disclosed

GRF(1-44) research alliance

NSC-665158: HIV-1 reverse transcriptase inhibitor analogue

Serostim FDA-approved for cachexia in AIDS patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...